187 related articles for article (PubMed ID: 8198928)
21. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.
Olkkola KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 1994 May; 55(5):481-5. PubMed ID: 8181191
[TBL] [Abstract][Full Text] [Related]
22. The influence of pretreatment periods with diltiazem on nifedipine kinetics.
Ohashi K; Sudo T; Sakamoto K; Tateishi T; Fujimura A; Kumagai Y; Ebihara A
J Clin Pharmacol; 1993 Mar; 33(3):222-5. PubMed ID: 8463435
[TBL] [Abstract][Full Text] [Related]
23. [Influence of verapamil and diltiazem on the muscle-relaxing effect of atracurium in vivo].
Gómez Iglesias E; García Pascual E; Aguirre Gómez C; Rodríguez-Sasiaín JM; Calvo Duo R
Rev Esp Anestesiol Reanim; 1991; 38(5):297-300. PubMed ID: 1665242
[TBL] [Abstract][Full Text] [Related]
24. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.
Ahonen J; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1997; 51(5):415-9. PubMed ID: 9049584
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of high-dose verapamil and diltiazem in the long-term treatment of stable exertional angina.
Weiner DA; McCabe CH; Cutler SS; Ryan TJ; Klein MD
Clin Cardiol; 1984 Dec; 7(12):648-53. PubMed ID: 6391771
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers.
Misaka S; Uchida S; Imai H; Inui N; Nishio S; Ohashi K; Watanabe H; Yamada S
Clin Exp Pharmacol Physiol; 2010 Mar; 37(3):290-5. PubMed ID: 19719748
[TBL] [Abstract][Full Text] [Related]
27. Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam.
Sawada T; Sako K; Yoshihara K; Nakamura K; Yokohama S; Hayashi M
J Pharm Sci; 2003 Apr; 92(4):790-7. PubMed ID: 12661064
[TBL] [Abstract][Full Text] [Related]
28. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
Mahgoub AA; El-Medany AH; Abdulatif AS
Saudi Med J; 2002 Jun; 23(6):725-31. PubMed ID: 12070557
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
[TBL] [Abstract][Full Text] [Related]
30. Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine.
Tateishi T; Ohashi K; Sudo T; Sakamoto K; Toyosaki N; Hosoda S; Toyo-oka T; Kumagai Y; Sugimoto K; Fujimura A
J Clin Pharmacol; 1989 Nov; 29(11):994-7. PubMed ID: 2600195
[TBL] [Abstract][Full Text] [Related]
31. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Varis T; Backman JT; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults.
Berg AK; Myrvik MJ; Van Ess PJ
Epilepsy Behav; 2017 Jun; 71(Pt A):51-59. PubMed ID: 28544992
[TBL] [Abstract][Full Text] [Related]
33. Analgesic effects of diltiazem and verapamil after central and peripheral administration in the hot-plate test.
Del Pozo E; Ruiz-García C; Baeyens JM
Gen Pharmacol; 1990; 21(5):681-5. PubMed ID: 2276585
[TBL] [Abstract][Full Text] [Related]
34. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
35. Effects of diltiazem on the pharmacokinetics of nifedipine.
Ohashi K; Tateishi T; Sudo T; Sakamoto K; Toyosaki N; Hosoda S; Toyo-oka T; Sugimoto K; Kumagai Y; Ebihara A
J Cardiovasc Pharmacol; 1990 Jan; 15(1):96-101. PubMed ID: 1688989
[TBL] [Abstract][Full Text] [Related]
36. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
37. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Takedomi S; Matsuo H; Sawada Y; Iga T
J Pharmacol Exp Ther; 2000 Mar; 292(3):1118-26. PubMed ID: 10688631
[TBL] [Abstract][Full Text] [Related]
38. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.
Wermeling DP; Record KA; Kelly TH; Archer SM; Clinch T; Rudy AC
Anesth Analg; 2006 Aug; 103(2):344-9, table of contents. PubMed ID: 16861415
[TBL] [Abstract][Full Text] [Related]
40. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.
Zimmermann T; Yeates RA; Laufen H; Scharpf F; Leitold M; Wildfeuer A
Arzneimittelforschung; 1996 Feb; 46(2):213-7. PubMed ID: 8720318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
